ABT vs SYK

• ABTKeep2.3%

  Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%).

• SYKBuy moresales growth, past year7.9%

  Stryker's sales grew 7.9% over the past year, but the stock fell 6.2% over the past five trading days, in step with other medical device makers (down 4.2%).

Percent return

• ABT−11.81%
• SYK−11.38%

1M6MYTD1Y5YMax

Nov 11, 2025 to Nov 11, 2026

Where they differ

Even, 3 each of 6

ABTSYK

• Company size: ABT $174B, SYK $135B.
  $174BbiggerCompany size$135B
• Sales growth, 1 yr: ABT +10%, SYK +7.9%. ABT is ahead.
  +10%Sales growth, 1 yr+7.9%
• Price for $1 of next year's profit: ABT $19, SYK $20. ABT is ahead.
  $19cheaperPrice for $1 of next year's profit$20
• Profit per $1 of sales: ABT 16¢, SYK 24¢. SYK is ahead.
  16¢Profit per $1 of sales24¢
• Cash minus debt: ABT −$27.1B, SYK −$12.2B. SYK is ahead.
  −$27.1BCash minus debt−$12.2B
• Price change, 1 yr: ABT −12%, SYK −11%. SYK is ahead. S&P 500 +12%.
  −12%Price change, 1 yr−11%
• How much the price swings: ABT 30%, SYK 41%. ABT is ahead.
  30%steadierHow much the price swings41%

Measure	ABTAbbott Laboratories	SYKStryker
Price and returns
Price	$109.35	$318.74
Today	Best in this row: −1.00%	−1.71%
1 month	+10.40%	Best in this row: +14.95%
3 months	Best in this row: +0.28%	−8.16%
This year	−10.60%	Best in this row: −8.52%
1 year	−11.81%	Best in this row: −11.38%
5 years	−5.13%	Best in this row: +27.57%
From 52-week high	−14.2%	−17.0%
How much it swings (90 days)	Best in this row: 30%	41%
Valuation
Market value	$174B	$135B
Price vs last year's earnings	Best in this row: 32.3×	40.8×
Price vs next year's expected earnings	Best in this row: 18.8×	20.4×
Price vs earnings, adjusted for growth	Best in this row: 1.65×	1.80×
Price to sales	Best in this row: 4.0×	4.7×
Price vs cash it brings in	28.2×	Best in this row: 27.1×
Company value vs operating profit	19.0×	Best in this row: 18.1×
Growth
Revenue growth, 1 year	Best in this row: +10.0%	+7.9%
Revenue growth a year, last 3 years	+0.5%	Best in this row: +10.8%
Earnings per share growth, last year	−53.4%	Best in this row: +16.3%
Earnings per share growth expected next year	+7.6%	Best in this row: +10.0%
Profitability
Kept from sales after making the product	57.2%	Best in this row: 65.7%
Kept as operating profit	15.7%	Best in this row: 24.0%
Kept as final profit	9.7%	Best in this row: 13.8%
Kept as spare cash	14.0%	Best in this row: 17.4%
Profit on shareholders' money	9.1%	Best in this row: 16.0%
Profit on all money put in	6.9%	Best in this row: 12.5%
Balance sheet
Net cash (cash minus debt)	−$27.1B	Best in this row: −$12.2B
Debt for each $1 of shareholders' money	Best in this row: 0.61×	0.66×
Short-term assets per $1 of bills due	1.45×	Best in this row: 2.18×
Dividend yield	Best in this row: 2.29%	1.08%
Share of profit paid as dividends	94%	Best in this row: 37%
Our readPro
Our call	Keep	Buy more
Why	Abbott Laboratories pays a 2.3% dividend that it has raised for 54 years in a row, but the stock fell 5.3% over the past five trading days, in step with other medical device makers (down 4.7%).	Stryker's sales grew 7.9% over the past year, but the stock fell 6.2% over the past five trading days, in step with other medical device makers (down 4.2%).
Where the price sits	in the full report	in the full report
Our overall score (out of 100)	57	Best in this row: 65
Our value score	Best in this row: 82	60
Our growth score	33	Best in this row: 62
Our quality score	68	Best in this row: 79
Our price trend score	Best in this row: 63	62
Earnings and analysts
Analyst consensus	Buy	Buy
To average analyst target	Best in this row: +11.5%	+5.9%
Average analyst target	$121.94	$337.53
Analysts rating it a buy	Best in this row: 82%	77%
Buy ratings added, 3 months	Best in this row: +2	0
Analysts covering	17	21

ABT: faster growth at a lower P/E

Our pick of these: Abbott Laboratories

Keep55/100

Sales growth +10.0% vs +7.9%

ABT +10.0%, SYK +7.9%.

ABT+10.0%

SYK+7.9%

Forward P/E per point of sales growth 1.88 vs 2.59

ABT 1.88, SYK 2.59.

ABT1.88

SYK2.59

+11.5% to the average analyst target, vs +5.9%

ABT +11.5%, SYK +5.9%.

ABT+11.5%

SYK+5.9%

Where it loses: SYK has a better call from us, Buy more vs Keep

• 2ndSYKBuy more45/100Would need faster sales growth, +7.9% vs +10.0%

Prices as of yesterday, 3:59 PM ET. A view, not advice.